Shares Magazine
0.55p+0.00 (+0.00%)16 Apr 2025, 16:30
Jump to:
Provexis PLC Fundamentals
| Company Name | Provexis PLC | Last Updated | 2025-04-16 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 2.346 bn | Market Cap | £12.90 m |
| PE Ratio | 0.39 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | £-0.00 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 2.3404 | Cash Equity Ratio | 1.3609 |
| Quick Ratio | 1.3226 | Current Ratio | 1.75 |
| Price To Book Value | 14.5773 | ROCE | 0 |
Provexis PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Provexis PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 |
| Stocks | £136,520.00 | £327,797.00 | £85,808.00 |
| Debtors | £125,479.00 | £61,114.00 | £104,443.00 |
| Cash & Equivalents | £189,357.00 | £379,121.00 | £863,873.00 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £498,036.00 | £845,992.00 | £1.13 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | £307,448.00 | £188,337.00 | £157,909.00 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £307,448.00 | £188,337.00 | £157,909.00 |
| Net assets | £190,588.00 | £657,655.00 | £969,080.00 |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | £2.22 m | £2.22 m | £2.21 m |
| Share Premium | £18.70 m | £18.70 m | £18.68 m |
| Profit / Loss | -£601,998.00 | -£419,916.00 | -£299,132.00 |
| Other Equity | £724,337.00 | £1.19 m | £1.50 m |
| Preference & Minorities | -£533,749.00 | -£531,874.00 | -£529,999.00 |
| Total Capital Employed | £190,588.00 | £657,655.00 | £969,080.00 |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 2.3404 | 2.3404 | 2.3404 |
| Cash / Equity | 1.3609 | 1.3609 | 1.3609 |
| EPS | £-0.00 | £-0.00 | £-0.00 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | -£191,498.00 | -£520,739.00 | -£213,615.00 |
| Cashflow before financing | -£191,498.00 | -£485,639.00 | -£213,615.00 |
| Increase in Cash | -£189,764.00 | -£484,752.00 | -£213,537.00 |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | £801,964.00 | £389,916.00 | £426,168.00 |
| Cost of sales | £518,169.00 | £95,497.00 | £46,119.00 |
| Gross Profit | £283,795.00 | £294,419.00 | £380,049.00 |
| Operating Profit | -£603,592.00 | -£420,927.00 | -£299,205.00 |
| Pre-Tax profit | -£601,998.00 | -£419,916.00 | -£299,132.00 |
Provexis PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant bloodclotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats. |
| Latest Interim Date | 31 Dec 2024 |
| Latest Fiscal Year End Date | 30 Sep 2024 |
Provexis PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2008-09-01 | Mr. Krijn Rietveld | Non-Executive Director |
| 2011-12-01 | Mr. Steven Neil Morrison | Executive Director,Chief Operating Officer |
| 2011-08-09 | Dr. Neville Clifford Bain | Non-Executive Director,Deputy Chairman |
| 2014-08-29 | Mr. Stephen Nigel Moon | Executive Director,Chief Executive Officer |
| 2024-09-30 | Mr. Charles Dawson Buck | Non-Executive Director,Chairman |
| 2025-01-07 | Mr. Ian Ford | Executive Director,CFO, CEO and Secretary |
| 2011-08-09 | Mr. Stewart William Slade BSc,ACA | Executive Director,Finance Director and Company Secretary |
| 2024-09-30 | Dr. Niamh Ann O'Kennedy | Executive Director,Chief Scientific Officer |
Provexis PLC Contact Details
| Company Name | Provexis PLC |
|---|---|
| Address | Prospect House, 58 Queens Road, Reading, RG1 4RP |
| Telephone | +44 7917670260 |
| Website | https://www.provexis.com |
Provexis PLC Advisors
| Solicitor | TLT LLP |
|---|
| Registrar | Equiniti Ltd. |
|---|---|
| Phone | +44 1214157082 |
| Stockbroker | Cenkos Securities |
|---|---|
| Phone | +44 2073978900 |
| Fax | +44 2073978901 |
| Financial PR Adviser | Haggie Partners LLP |
|---|---|
| Phone | +44 2075624444 |
| Nominated Adviser | Cenkos Securities |
|---|---|
| Phone | +44 2073978900 |
| Fax | +44 2073978901 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Dunelm Group PLC | 1,074.00 | 13.29 |
| Asos PLC | 313.50 | 6.63 |
| Rentokil Initial PLC | 350.00 | 5.01 |
| Sainsbury (J) PLC | 256.80 | 3.55 |
| Dr. Martens PLC | 52.80 | 3.53 |
| Pershing Square Holdings LTD | 3,414.00 | 3.45 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Dowlais Group PLC | 51.40 | -6.03 |
| Fresnillo PLC | 1,021.00 | -5.55 |
| Jupiter Fund Management PLC | 69.30 | -5.07 |
| Goodwin PLC | 6,780.00 | -4.51 |
| Spectris PLC | 1,987.00 | -4.38 |
| Twentyfour Income Fund Limited | 108.60 | -3.89 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.